This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Dostinex (cabergoline) Prescribing Information (external link) Adverse event reporting information can be found at the bottom of the page
For the treatment of hyperprolactinaemic disorders the initial dosage of DOSTINEX is 0.5mg per week, given in one or two (one-half of one 0.5mg tablets i.e. 0.25mg) doses per week.1
The weekly dose should be increased gradually, preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved. 1
The therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week. 1
The maximum dose should not exceed 3mg per day. 1
The weekly dose may be given as a single administration or divided into two or more doses per week according to patient tolerability. Division of the weekly dose into multiple administrations is advised when doses higher than 1 mg per week are to be given since the tolerability of doses greater than 1 mg taken as a single weekly dose has been evaluated only in a few patients. 1
44% (n=104/236) of patients taking daily bromocriptine for hyperprolactinaemic amenorrhoea missed a dose vs. 18% (n=40/223) with twice-weekly DOSTINEX missing at least one dose (during open-label period).2
View clinical trial data to show proven efficacy in hyperprolactinaemia & lactation suppression with DOSTINEX
View the safety profile for DOSTINEX
Explore more including a snapshot of DOSTINEX and a video explaining how DOSTINEX works to lower prolactin levels
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021